Pricing Log in Create free account
Friday 6 November 2026 Export WGS’s income statement to Excel — free account

GeneDx Holdings Corp.

WGS Healthcare Diagnostics & Research

GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.

Revenue
+11.4%
EPS
−257.9%
Free cash flow
−585.6%
Total debt
+87.4%

Quarter to June 2026, against a year earlier

65.16 0.80 +1.24%
Market cap
$1.9B
P/E
0.0×
Fwd P/E
−20.6×
Dividend yield
—
F-score
6/9
Altman Z
7.80
Beneish M
−2.36
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

GeneDx Holdings Corp. (WGS) P/E ratio

Alert me on P/E ratio

GeneDx Holdings Corp. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 1,893× (September 2025) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 979× (25.73%)
19 more quarters

Against its own ten years

Low 0.0× High 1,893×
Ten-year median 0.0×
Current reading's percentile 91

P/E ratio against peers

Company P/E ratio
WGS GeneDx Holdings Corp. n/m
CSTL Castle Biosciences, Inc. compare n/m
NEO NeoGenomics, Inc. compare n/m
OPK OPKO Health, Inc. compare n/m
FRNM Freenome, Inc compare n/m
PSNL Personalis, Inc. compare n/m
ADPT Adaptive Biotechnologies Corporation compare n/m
VCYT Veracyte, Inc. compare 15.2×
CDNA CareDx, Inc. compare 30.9×
Diagnostics & Research industry median 34.5×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on WGS